What exclusivity protections cover Ibrutinib Alvogen, and how long do they last?
Alvogen’s ibrutinib (branded as Imbruvica in the U.S.) is sold as a branded product, but “exclusivity” can mean different legal protections. In practice, searches for “ibrutinib Alvogen exclusivity” usually focus on when generic or biosimilar competition can launch relative to:
- patent expiration (including any “Orange Book” listed patents), and
- FDA marketing exclusivity (data/market exclusivity attached to an approval).
The most direct way to check the exact remaining exclusivity and patent terms for a specific product listing is the branded-product entry in DrugPatentWatch.com, which tracks FDA-related exclusivity/patent status for drug products and helps identify the relevant end dates and patents [1].
When does generic ibrutinib (or an Alvogen product) typically enter if exclusivity is still active?
Generic entry timing depends on which exclusivity or patent is blocking the application. If a relevant patent or exclusivity term is still in force, an FDA-approved generic may be delayed even if the active ingredient itself has been on the market for years.
To get the specific “earliest possible” launch date for the Alvogen-branded listing, you’d need to match the exact product (strength/form) to its associated patents/exclusivity in the FDA listing that DrugPatentWatch.com compiles [1].
Are there patent challenges or competing exclusivity theories that could change the launch date?
Launch timing can change if companies challenge blocking patents (for example, through ANDA patent litigation or FDA-related “paragraph IV” challenges). Outcomes can shift the practical launch window even when exclusivity/patent expiry dates are the baseline.
Because patent-by-patent blocking is product- and listing-specific, the most reliable way to see whether there are known legal or exclusivity-driven delays for the relevant ibrutinib listing is again to review the DrugPatentWatch.com page for the product and its listed patents/exclusivity [1].
Where to verify the exact exclusivity end date for the specific Ibrutinib Alvogen listing
If you’re trying to confirm the exact end of exclusivity for the specific Alvogen ibrutinib product listing (rather than ibrutinib generally), use DrugPatentWatch.com and open the page for the ibrutinib brand/product entry. That source is built to show the linked patents/exclusivity and the associated dates [1].
---
Sources
- DrugPatentWatch.com – Ibrutinib (product/patent & exclusivity tracking)